| Status | In progress |
| Process | STA 2018 |
| ID number | 3802 |
Provisional Schedule
| Committee meeting: 1 | 07 September 2021 |
Project Team
| Project lead | Michelle Adhemar |
Email enquiries
- If you have any queries please email TAteam2@nice.org.uk
| Evidence Review Group / Assessment Group | Warwick Evidence, Warwick Medical School, University of Warwick |
Consultees
| Companies sponsors | GlaxoSmithKline (dostarlimab) |
| Others | Department of Health and Social Care |
| NHS England | |
| NHS Richmond CCG | |
| NHS South East Staffordshire & Seisdon Peninsular | |
| Welsh Government | |
| Patient carer groups | Black Health Agency |
| Cancer Black Care | |
| Cancer Equality | |
| Cancer 52 | |
| Endometriosis UK | |
| Eve Appeal | |
| Go Girls | |
| Helen Rollason Cancer Charity | |
| Independent Cancer Patients Voice | |
| Jo’s Cervical Cancer Trust | |
| Macmillan Cancer Support | |
| Maggie’s Centres | |
| Marie Curie | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| Tenovus Cancer Care | |
| Wellbeing of Women | |
| Professional groups | Association of Cancer Physicians |
| Association of Surgeons of Great Britain and Ireland | |
| British Association of Surgical Oncology | |
| British Geriatrics Society | |
| British Gynaecological Cancer Society | |
| British Institute of Radiology | |
| British Psychosocial Oncology Society | |
| British Society for Clinical Cytology | |
| British Society for Colposcopy and Cervical Pathology | |
| Cancer Research UK | |
| National Forum of Gynaecological Oncology Nurses | |
| Royal College of Anaesthetists | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Obstetricians & Gynaecologists | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Royal College of Surgeons | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| Society and College of Radiographers | |
| UK Clinical Pharmacy Association | |
| UK Health Forum | |
| UK Oncology Nursing Society |
Commentators
| Associated public health groups | Public Health England |
| Public Health Wales | |
| Comparator companies | Accord Healthcare (carboplatin, doxorubicin, paclitaxel) |
| Bausch and Lomb UK (megestrol) | |
| Janssen-Cilag (doxorubicin) | |
| Hospira UK (carboplatin, paclitaxel) | |
| Medac GmbH (doxorubicin) | |
| Pfizer (doxorubicin, medroxyprogesterone acetate) | |
| Seacross Pharmaceuticals (doxorubicin, paclitaxel) | |
| General commentators | Allied Health Professionals Federation |
| All Wales Therapeutics and Toxicology Centre | |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Care Quality Commission | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| National Pharmacy Association | |
| NHS Alliance | |
| NHS Confederation | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Cochrane Gynaecological Cancer Group |
| Genomics England | |
| Institute of Cancer Research | |
| MRC Clinical Trials Unit | |
| National Cancer Research Institute | |
| National Cancer Research Network | |
| National Institute for Health Research | |
| Peaches Womb Cancer Trust |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 14 January 2021 | Invitation to participate |
| 01 October 2020 - 29 October 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 15 October 2020 | In progress. DHSC referral received |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance